Tutorials
Ocugen Inc logo

Ocugen Inc

$ 2.86 +0.09 (+3.25%) 10:08 PM EST
P/E:
At Loss
P/B:
4.70
Market Cap:
$ 616.79M
Enterprise V:
$ 490.19M
Volume:
6.01M
Avg Vol (2M):
6.07M
Also Trade In:
Volume:
6.01M
Market Cap $:
616.79M
PE Ratio:
At Loss
Avg Vol (2-Month):
6.07M
Enterprise Value $:
490.19M
PB Ratio:
4.70
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%
Alerts Website SEC Filings Stock Report
Dataset
Financial Download Tutorials

Business Description

Ocugen Inc
NAICS : 325412 SIC : 2834
263 Great Valley Parkway, Malvern, PA, USA, 19355
Description
Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19. The breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with one drug one to many and novel biologic product candidate aims to offer better therapy to patients with underserved diseases such as wet age-related macular degeneration, diabetic macular edema and diabetic retinopathy. The company is co-developing Bharat Biotech's COVAXIN vaccine candidate for COVID-19 in the U.S. and Canadian markets.
Name Current Vs Industry Vs History
Cash-To-Debt 41
Equity-to-Asset 0.93
Debt-to-Equity 0.02
Debt-to-EBITDA -0.05
Piotroski F-Score 4/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score -3.82
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate 80.6
3-Year EPS without NRI Growth Rate 81.5
3-Year FCF Growth Rate 79.4
Name Current Vs Industry Vs History
5-Day RSI 77.39
9-Day RSI 65.16
14-Day RSI 60.17
6-1 Month Momentum % -27.58
12-1 Month Momentum % -65.29

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 17.96
Quick Ratio 17.96
Cash Ratio 16.88

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -477.8

Financials (Next Earnings Date:2022-11-09 Est.)

OCGN's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:OCGN

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -0.34
Beta 4.19
Volatility % 99.69
14-Day RSI 60.17
14-Day ATR ($) 0.205179
20-Day SMA ($) 2.64
12-1 Month Momentum % -65.29
52-Week Range ($) 1.67 - 17.65
Shares Outstanding (Mil) 215.66

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 4
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Ocugen Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More